Drugs / Oxyntomodulin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01373450 | Jun → Jul 2011 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 1 | NCT01055340 | Apr → May 2010 | obesity disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oxyntomodulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01055340 ↗ |
| Known as | OXM | “Oxyntomodulin (OXM), an enteroendocrine hormone, causes appetite suppression, increased energy expenditure, and weight loss in obese humans via activation of GLP-1 and glucagon...” PMID 29545266 ↗ Mar 2018 |
| Action | Activate | “via activation of GLP-1 and glucagon receptors” PMID 29545266 ↗ Mar 2018 |
| Modality | Protein / enzyme biologic | — CHEMBL2401865 ↗ |
| Route | Intravenous | “Single infusion of OXM 3.0 pmol/kg/min by IV” NCT01055340 ↗ |